Therapeutic potential of icatibant (HOE-140, JE-049)

Bibliography

• Lembeck F, Griesbacher T, Eckhardt M, et al. New, long-acting, potent bradykinin antagonists. Br J Pharmacol 1991;102:297-304
   PubMed Web of Science ®Google Scholar
• Hock FJ, Wirth K, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 1991;102:769-73
   PubMed Web of Science ®Google Scholar
• Wirth K, Hock FJ, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 1991;102:774-7
   PubMed Web of Science ®Google Scholar
• Leeb-Lundberg LM, Marceau F, Muller-Esterl W, et al. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005;57:27-77
   PubMed Web of Science ®Google Scholar
• Moreau ME, Garbacki N, Molinaro G, et al. The kallikrein–kinin system: current and future pharmacological targets. J Pharmacol Sci 2005;99:6-38
   PubMed Web of Science ®Google Scholar
• Bas M, Adams V, Suvorava T, et al. Nonallergic angioedema: role of bradykinin. Allergy 2007;62:842-56
   PubMed Web of Science ®Google Scholar
• McLean PG, Perretti M, Ahluwalia A. Kinin B(1) receptors and the cardiovascular system: regulation of expression and function. Cardiovasc Res 2000;48:194-210
   PubMed Web of Science ®Google Scholar
• Marin-Castano ME, Schanstra JP, Neau E, et al. Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation 2002;105:627-32
   PubMed Web of Science ®Google Scholar
• Bachvarov DR, Saint-Jacques E, Larrivee JF, et al. Cloning and pharmacological characterization of the rabbit bradykinin B2 receptor. J Pharmacol Exp Ther 1995;275:1623-30
   PubMed Web of Science ®Google Scholar
• Wagner F, Rosenkranz B, Knolle J. Absolute bioavailability of subcutaneously administered icatibant, a selective and potent bradykinin B2 receptor antagonist. J Allergy Clin Immunol 2007;119:S274
   Web of Science ®Google Scholar
• Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist. Br J Clin Pharmacol 1994;38:317-21
   PubMed Web of Science ®Google Scholar
• Proud D, Bathon JM, Togias AG, Naclerio RM. Inhibition of the response to nasal provocation with bradykinin by HOE-140: effi cacy and duration of action. Can J Physiol Pharmacol 1995;73:820-6
   PubMed Web of Science ®Google Scholar
• Brown NJ, Gainer JV, Murphey LJ, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation 2000;102:2190-6
   PubMed Web of Science ®Google Scholar
• Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 2007;119:1497-503
   PubMed Web of Science ®Google Scholar
• Witherow FN, Helmy A, Webb DJ, et al. Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation 2001;104:2177-81
   PubMed Web of Science ®Google Scholar
• Davie AP, Dargie HJ, McMurray JJ. Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. Circulation 1999;100:268-73
   PubMedGoogle Scholar
• Squire IB, O'Kane KP, Anderson N, Reid JL. Bradykinin B(2) receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men. Hypertension 2000;36:132-6
   PubMed Web of Science ®Google Scholar
• Gainer F, JV, Morrow JD, Loveland A, et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1286-92
   Google Scholar
• Cruden NL, Witherow FN, Webb DJ, et al. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Arterioscler Thromb Vasc Biol 2004;24:1043-8
   PubMed Web of Science ®Google Scholar
• Murphey LJ, Kumar S, Brown NJ. Endogenous bradykinin and the renin and pressor responses to furosemide in humans. J Pharmacol Exp Ther 2000;295:644-8
   PubMedGoogle Scholar
• Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol 2005;53:373-88; quiz 389-92
   PubMed Web of Science ®Google Scholar
• Bowen T, Cicardi M, Bork K, et al. Hereditary angiodema: a current state-of-the-art review. VII. Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol 2008;100:S30-40
   Web of Science ®Google Scholar
• Bas M, Bier H, Greve J, et al. Novel pharmacotherapy of acute hereditary angioedema with bradykinin B2-receptor antagonist icatibant. Allergy 2006;61:1490-2
   PubMed Web of Science ®Google Scholar
• Schreiber AD, Kaplan AP, Austen KF. Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest 1973;52:1402-9
   PubMed Web of Science ®Google Scholar
• Ratnoff OD, Pensky J, Ogston D, Naff GB. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor. J Exp Med 1969;129:315-31
   PubMed Web of Science ®Google Scholar
• Gigli I, Mason JW, Colman RW, Austen KF. Interaction of plasma kallikrein with the C1 inhibitor. J Immunol 1970;104:574-81
   PubMed Web of Science ®Google Scholar
• Schapira M, Silver LD, Scott CF, et al. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med 1983;308:1050-3
   PubMed Web of Science ®Google Scholar
• Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet 1998;351:1693-7
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Silverberg M, Ghebrehiwet B, et al. Pathways of kinin formation and role in allergic diseases. Clin Immunol Immunopathol 1989;50:S41-51
   Google Scholar
• Nussberger J, Cugno M, Cicardi M, Agostoni A. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 1999;104:1321-2
   PubMed Web of Science ®Google Scholar
• Lung CC, Chan EK, Zuraw BL. Analysis of an exon 1 polymorphism of the B2 bradykinin receptor gene and its transcript in normal subjects and patients with C1 inhibitor deficiency. J Allergy Clin Immunol 1997;99:134-46
   PubMed Web of Science ®Google Scholar
• Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002;109:1057-63
   PubMed Web of Science ®Google Scholar
• Boehm T, Lumry WR. Resolution of symptoms in a patient with hereditary angioedema (HAE) following treatment with icatibant, a potent and selective bradykinin-2 receptor antagonist. J Allergy Clin Immunol 2007;119:S279
   Google Scholar
• JERINI. Jerini announces positive results from two phase III trials of icatibant for the treatment of hereditary angioedema. Available from: http://www.jerini.com/ cms/en/pdfreleases/060921_toplineresults_EN.pdf [Last accessed 22 April 2008]
   Google Scholar
• Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am 2006;26:725-37
   PubMed Web of Science ®Google Scholar
• Emanueli C, Grady EF, Madeddu P, et al. Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension 1998;31:1299-304
   PubMed Web of Science ®Google Scholar
• Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol 2003;3:311-7
   PubMed Web of Science ®Google Scholar
• Agostoni A, Cicardi M, Cugno M, et al. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology 1999;44:21-5
   PubMedGoogle Scholar
• Molinaro G, Cugno M, Perez M, et al. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J Pharmacol Exp Ther 2002;303:232-7
   PubMed Web of Science ®Google Scholar
• Coats AJ. Omapatrilat: the story of overture and octave. Int J Cardiol 2002;86:1-4
   PubMed Web of Science ®Google Scholar
• Byrd JB, Touzin K, Sile S, et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension 2008;51:141-7
   PubMed Web of Science ®Google Scholar
• Bas M, Hoffmann TK, Bier H, Kojda G. Increased C-reactive protein in ACE-inhibitor-induced angioedema. Br J Clin Pharmacol 2005;59:233-8
   PubMed Web of Science ®Google Scholar
• Bas M, Kirchhartz N, Hochfeld J, et al. Potential role of vasomotor effects of fibrinogen in bradykinin-induced angioedema. J Allergy Clin Immunol 2008;121:969-75, e2
   PubMedGoogle Scholar
• Sakamoto T, Elwood W, Barnes PJ, Chung KF. Effect of Hoe 140, a new bradykinin receptor antagonist, on bradykinin- and platelet-activating factor-induced bronchoconstriction and airway microvascular leakage in guinea pig. Eur J Pharmacol 1992;213:367-73
   PubMedGoogle Scholar
• Sakamoto T, Sun J, Barnes PJ, Chung KF. Effect of a bradykinin receptor antagonist, HOE 140, against bradykinin- and vagal stimulation-induced airway responses in the guinea-pig. Eur J Pharmacol 1994;251:137-42
   PubMedGoogle Scholar
• Turner P, Dear J, Scadding G, Foreman JC. Role of kinins in seasonal allergic rhinitis: icatibant, a bradykinin B2 receptor antagonist, abolishes the hyperresponsiveness and nasal eosinophilia induced by antigen. J Allergy Clin Immunol 2001;107:105-13
   PubMed Web of Science ®Google Scholar
• Akbary AM, Wirth KJ, Scholkens BA. Efficacy and tolerability of icatibant (Hoe 140) in patients with moderately severe chronic bronchial asthma. Immunopharmacology 1996;33:238-42
   PubMed Web of Science ®Google Scholar
• Cugno M, Salerno F, Nussberger J, et al. Bradykinin in the ascitic fluid of patients with liver cirrhosis. Clin Sci (Lond) 2001;101:651-7
   PubMedGoogle Scholar
• Wirth KJ, Bickel M, Hropot M, et al. The bradykinin B2 receptor antagonist Icatibant (HOE 140) corrects avid Na+ retention in rats with CCl4-induced liver cirrhosis: possible role of enhanced microvascular leakage. Eur J Pharmacol 1997;337:45-53
   PubMedGoogle Scholar
• Russman S, Decosterd L, Buclin T, et al. The bradykinin antagonist icatibant increases electrolyte and water excretion in patients with liver cirrhosis. Clin Pharmacol Ther 2004;75:P12
   Google Scholar
• Jonkam CC, Enkhbaatar P, Nakano Y, et al. Effects of the bradykinin B2 receptor antagonist icatibant on microvascular permeability after thermal injury in sheep. Shock 2007;28:704-9
   PubMedGoogle Scholar
• Yekebas E, Treede H, Jochum M, et al. Bradykinin B2-receptor antagonism attenuates fatal cardiocirculatory breakdown induced by severe experimental pancreatitis. Crit Care Med 2000;28:1119-27
   PubMedGoogle Scholar
• Hirata M, Hayashi I, Yoshimura K, et al. Blockade of bradykinin B(2) receptor suppresses acute pancreatitis induced by obstruction of the pancreaticobiliary duct in rats. Br J Pharmacol 2002;135:29-36
   PubMedGoogle Scholar
• Feletou M, Jamonneau I, Germain M, et al. Bradykinin B2 receptor involvement in rabbit and murine models of septic shock. J Cardiovasc Pharmacol 1996;27:500-7
   PubMed Web of Science ®Google Scholar
• Siebeck M, Spannagl E, Schorr M, et al. Effect of combined B1 and B2 kinin receptor blockade in porcine endotoxin shock. Immunopharmacology 1996;33:81-4
   PubMedGoogle Scholar
• Schouten JW. Neuroprotection in traumatic brain injury: a complex struggle against the biology of nature. Curr Opin Crit Care 2007;13:134-42
   PubMed Web of Science ®Google Scholar
• XYTIS. Xytis begins phase II clinical study with anatibant (XY2405) for traumatic brain injury ‘Brain Trial’ (Bradykinin B2 Receptor-Antagonist-‘Anatibant’ In Neurotrauma). Available from: http://www.xytis.com/Media/phase2tbijan2007.html [Last accessed 22 April 2008]
   Google Scholar